#1 Clinical Trials Search in Europe

Magnetic Resonance Imaging Contrast Media

This article explores the use of Magnetic Resonance Imaging (MRI) Contrast Media in clinical trials for multiple sclerosis (MS). MRI contrast media play a crucial role in these studies by enhancing the visibility of brain and spinal cord lesions, helping researchers assess the progression of MS and the effectiveness of new treatments. The trials discussed focus on investigating the long-term safety and efficacy of drugs like tolebrutinib in patients with various forms of MS, including relapsing and progressive types.

Table of Contents

What is Magnetic Resonance Imaging Contrast Media?

Magnetic Resonance Imaging (MRI) contrast media are substances used to enhance the visibility of internal body structures in MRI scans. These contrast agents are typically injected into the body before or during an MRI examination to improve the clarity and detail of the images produced[1]. MRI contrast media are not drugs that treat diseases directly, but rather tools that help doctors better visualize and diagnose various medical conditions.

Use in Multiple Sclerosis Research

In the context of multiple sclerosis (MS) research, MRI contrast media play a crucial role in assessing the progression and treatment of the disease. The clinical trials described in the source documents focus on investigating treatments for various forms of MS, including:

  • Relapsing Multiple Sclerosis (RMS): A form of MS characterized by periods of symptom flare-ups followed by periods of remission.
  • Primary Progressive Multiple Sclerosis (PPMS): A type of MS where symptoms steadily worsen from the onset without distinct relapses or remissions.
  • Secondary Progressive Multiple Sclerosis (SPMS): A stage that may follow relapsing-remitting MS, where the disease begins to progress more steadily.

MRI contrast media are used in these studies to help researchers evaluate the effectiveness of experimental treatments by allowing them to visualize changes in the brain and spinal cord more clearly[1][2].

Administration and Safety

MRI contrast media are typically administered as a solution for injection. This means that the contrast agent is given through an intravenous (IV) line directly into the bloodstream[1][2]. It’s important to note that while these agents are generally considered safe, they are used under careful medical supervision.

Patients participating in clinical trials where MRI contrast media are used should be aware of the following safety considerations:

  • Inform your doctor about any allergies or previous reactions to contrast agents.
  • Discuss any kidney problems with your healthcare provider, as some contrast agents may affect kidney function.
  • Follow all instructions provided by the medical team regarding preparation for the MRI scan.

Role in Clinical Trials

In the clinical trials described, MRI contrast media are used as a tool to assess the efficacy of experimental treatments for multiple sclerosis. Specifically, they help researchers measure:

  1. New and/or enlarging T2-hyperintense lesions: These are areas of damage in the central nervous system that can be seen on MRI scans. The number of these lesions per year is an important measure of disease activity[1][2].
  2. Changes in total volume of T2-hyperintense lesions: This measure helps track the overall burden of disease over time[1][2].

By using MRI contrast media, researchers can obtain more detailed and accurate images of the brain and spinal cord. This allows them to better understand how the experimental treatments are affecting the progression of MS in study participants[1][2].

It’s important to understand that while MRI contrast media are crucial for assessing the effectiveness of MS treatments in these trials, they are not treatments themselves. Instead, they are diagnostic tools that help researchers and doctors make more informed decisions about patient care and treatment efficacy.

Aspect Details
Study Type Phase 3 extension study
Main Objective Investigate long-term safety and tolerability of tolebrutinib in MS patients
MS Types Studied Relapsing MS, Primary Progressive MS, Non-relapsing Secondary Progressive MS
Primary Endpoints Number of participants with adverse events, serious adverse events, and events leading to discontinuation
Secondary Endpoints Time to disability progression, relapse rate, new/enlarging T2 lesions, changes in T2 lesion volume
Role of MRI Contrast Media Used to enhance visibility of brain lesions for assessing disease progression and treatment efficacy
Key Exclusion Criteria Active infections, liver disease, alcohol use disorder, significant bleeding risks

FAQ

  • What is Magnetic Resonance Imaging Contrast Media? Magnetic Resonance Imaging (MRI) Contrast Media are substances used during MRI scans to enhance the visibility of certain tissues or abnormalities. In MS trials, they help researchers better visualize brain and spinal cord lesions associated with the disease.
  • How is MRI Contrast Media used in MS clinical trials? MRI Contrast Media is used to assess changes in brain lesions over time. In the trials mentioned, it helps measure the number of new or enlarging T2-hyperintense lesions per year and changes in the total volume of these lesions, which are indicators of disease progression and treatment effectiveness.
  • What types of MS are being studied in these clinical trials? The trials are investigating treatments for various forms of MS, including relapsing multiple sclerosis (RMS), primary progressive multiple sclerosis (PPMS), and non-relapsing secondary progressive multiple sclerosis (NRSPMS).
  • What is the main objective of these clinical trials? The main objective of these trials is to determine the long-term safety and tolerability of tolebrutinib, a drug being studied for MS treatment. They also aim to assess its long-term efficacy on disability progression, relapse rate, and MRI parameters in participants with different forms of MS.
  • How do researchers measure the effectiveness of the treatment in these trials? Researchers measure effectiveness through various means, including the time to onset of confirmed disability worsening or progression, annualized relapse rate (for RMS patients), the number of new or enlarging brain lesions seen on MRI, and changes in the total volume of these lesions.

Ongoing Clinical Trials on Magnetic Resonance Imaging Contrast Media

  • Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on Long-Term Safety of Tolebrutinib for Patients with Relapsing or Progressive Multiple Sclerosis

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark The Netherlands

Glossary

  • Magnetic Resonance Imaging (MRI): A medical imaging technique that uses powerful magnets and radio waves to create detailed images of the body's internal structures, particularly useful for examining the brain and spinal cord in MS patients.
  • T2-hyperintense lesions: Areas of damage or inflammation in the brain or spinal cord that appear bright on certain types of MRI scans. These lesions are characteristic of MS and are used to track disease progression.
  • Relapsing Multiple Sclerosis (RMS): A form of MS characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • Progressive Multiple Sclerosis (PMS): Forms of MS where neurologic function worsens steadily over time, with or without relapses. This includes primary progressive MS and secondary progressive MS.
  • Tolebrutinib: An investigational drug being studied for its potential to treat various forms of multiple sclerosis.
  • Annualized Relapse Rate (ARR): A measure used in MS research to quantify the number of relapses a patient experiences per year, helping to assess the effectiveness of treatments in reducing disease activity.
  • Confirmed Disability Worsening (CDW): A sustained increase in disability score, typically measured over a period of 3 or 6 months, used to assess disease progression in MS patients.
  • Open Label (OL): A type of clinical trial where both the researchers and participants know which treatment is being administered, as opposed to a blinded study.

References

  1. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-tolebrutinib-for-patients-with-relapsing-or-progressive-multiple-sclerosis/
  2. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-tolebrutinib-and-teriflunomide-for-patients-with-multiple-sclerosis/